Budgets for biopharmaceutical activities are gaining in select functional areas except outsourcing.
Eric Langer
Advertisement
Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.
Articles by Eric Langer
Budgets for biopharmaceutical activities are gaining in select functional areas except outsourcing.
Industry wants more innovation, but can suppliers meet customer needs?
Industry wants more innovation, but can suppliers meet customer needs?
The industry wants more innovation, but can suppliers meet customers' needs?
Industry optimism is on the rise for 2012.
Industry optimism is on the rise for 2012.
Biosimilar manufacturers need better expression systems and analytical tools to compete.
Biosimilar manufacturers need better expression systems and analytical tools to compete.
China rises to the top as a destination for international outsourcing.
China rises to the top as a destination for international outsourcing.
A recent industry survey shows keen interest in improving bioreactors and cell-culture media.
A recent industry survey shows keen interest in improving bioreactors and cell-culture media.
More crucial biomanufacturing operations are expected to be outsourced.
More crucial biomanufacturing operations are expected to be outsourced.
Post recession and beyond, which contract service providers will still be standing?
Relationship management is a limiting factor to growth in biomanufacturing outsourcing.
Relationship management is a limiting factor to growth in biomanufacturing outsourcing.
Restructuring in the biopharmaceutical industry is renewing a focus on resource optimization.
Restructuring in the biopharmaceutical industry is renewing a focus on resource optimization.
Strategic rather than tactical considerations are driving biopharmaceutical outsourcing.
Strategic rather than tactical considerations are driving biopharmaceutical outsourcing.
Biopharmaceutical companies generally try to avoid paying royalties on novel technologies, including novel expression systems, in part because of the inability to predict revenue flow after a product is commercialized.
There may well be a pending revolution in biopharmaceutical expression systems. Nearly 50% of biomanufacturers today are demanding a whole lot more from their primary expression systems than they have during the past 30 years.
Although the CRO may not wish to draw attention to weaknesses in the intended trial, failing to do so is a great disservice.
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FAQ: Pharmaceutical Outsourcing Trends and Innovations
2
FAQ: Everything to Know about 3D Printing in Pharma Manufacturing and Packaging
3
Lilly Launches UK Trial of Weight-Loss Drug as US Price Drops
4
Drug Solutions Podcast: Innovations in Orphan Drugs for Rare Diseases
5
